Janssen submits Marketing Authorisation Application for Simeprevir to the EMA
24 April 2013 | By Burson-Marsteller
Janssen has submitted a MAA to the EMA seeking approval for simeprevir...
List view / Grid view
24 April 2013 | By Burson-Marsteller
Janssen has submitted a MAA to the EMA seeking approval for simeprevir...
24 April 2013 | By Sanofi Pasteur
Company also expands injectable polio vaccine production capacity...
24 April 2013 | By Novartis
Novartis announced the compensation for the incoming Chairman of the Board, starting August 1, 2013...
24 April 2013 | By Boehringer Ingelheim
Net sales rose by 11.5 percent to around €14.7 billion...
23 April 2013 | By Merck
Merck announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial...
23 April 2013 | By TEVA
"We are very pleased to receive orphan drug designation for XEN402..."
23 April 2013 | By Gilead Sciences
Detailed results from four Phase 3 clinical trials...
23 April 2013 | By Alchemia Limited
Alchemia has signed a multi-target, drug discovery collaboration with AstraZeneca...
23 April 2013 | By Boehringer Ingelheim
Results from the pivotal Phase III STARTVerso™1 trial...
23 April 2013 | By Novartis
Results from the 64-week SPARK study...
23 April 2013 | By Roche
Measures aim to ensure sustained success in a fast-changing market environment...
22 April 2013 | By Amgen
Amgen welcomes a new report from the European Commission...
22 April 2013 | By H. Lundbeck A/S
Lundbeck launches Selincro®...
22 April 2013 | By Daiichi Sankyo
Daiichi Sankyo announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., has begun marketing silodosin...
22 April 2013 | By Sanofi Pasteur
Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine...